Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Recruiting · NCT05841472 · Registry updated 2023-08-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer | Recruiting | Phase 2 | 2023-08-30 | NCT05841472 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CrystalGenomics, Inc. | 1 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Busan National University Hospital Yangsan | Yangsan | South Korea | 1 |
| Catholic University of Korea EunPyeong St. Mary's Hospital | Seoul | South Korea | 1 |
| Catholic University of Korea Yeouido St. Mary's Hospital | Seoul | South Korea | 1 |
| Chonnam National University Hwasun Hospital | Hwasun | South Korea | 12 |
| Hallym University Sacred Heart Hospital | Anyang | South Korea | 12 |
| Korea University Anam Hospital | Anam | South Korea | 1 |
| Korea University Guro Hospital | Seoul | South Korea | 57 |
| Seoul Asan Hospital | Seoul | South Korea | 2 |